RESUMO
Xenotransplantation offers the potential to meet the critical need for heart and lung transplantation presently constrained by the current human donor organ supply. Much was learned over the past decades regarding gene editing to prevent the immune activation and inflammation that cause early organ injury, and strategies for maintenance of immunosuppression to promote longer-term xenograft survival. However, many scientific questions remain regarding further requirements for genetic modification of donor organs, appropriate contexts for xenotransplantation research (including nonhuman primates, recently deceased humans, and living human recipients), and risk of xenozoonotic disease transmission. Related ethical questions include the appropriate selection of clinical trial participants, challenges with obtaining informed consent, animal rights and welfare considerations, and cost. Research involving recently deceased humans has also emerged as a potentially novel way to understand how xeno-organs will impact the human body. Clinical xenotransplantation and research involving decedents also raise ethical questions and will require consensus regarding regulatory oversight and protocol review. These considerations and the related opportunities for xenotransplantation research were discussed in a workshop sponsored by the National Heart, Lung, and Blood Institute, and are summarized in this meeting report.
Assuntos
Transplante de Coração , Transplante de Pulmão , Transplante Heterólogo , Transplante Heterólogo/ética , Humanos , Transplante de Pulmão/ética , Animais , Estados Unidos , Transplante de Coração/ética , National Heart, Lung, and Blood Institute (U.S.) , Pesquisa Biomédica/ética , Doadores de Tecidos/provisão & distribuição , Doadores de Tecidos/éticaRESUMO
Rules are needed for human research in commercial spaceflight.
Assuntos
Experimentação Humana , Sujeitos da Pesquisa , Voo Espacial , Humanos , Voo Espacial/ética , Experimentação Humana/ética , Experimentação Humana/legislação & jurisprudênciaRESUMO
Over time, ethical judgments evolve, but so do the phenomena they are applied to. For example, plagiarism is a modern concept. Before the early eighteenth century, works did not generally have references or acknowledgments, and ideas were freely exchanged. As writing became an occupation, copying others' words became "unethical." As cut and paste, music mash-up, and other technological forms of exchange make copying the works of others simple, the idea of plagiarism is eroding, and perhaps will eventually even be discarded. The same may be true with privacy. As with plagiarism, it was not really until the eighteenth century that our modern idea of privacy was established. To younger generations, raised on social media, online life is predicated on trading personal information for access. The undermining of former standards of privacy may suggest that privacy may also eventually become an outmoded concept.
Assuntos
Plágio , Mídias Sociais , Humanos , Privacidade , Tecnologia , RedaçãoRESUMO
The American Society of Nephrology, the European Renal Association-European Dialysis and Transplant Association and the International Society of Nephrology Joint Working Group on Ethical Issues in Nephrology have identified ten broad areas of ethical concern as priority challenges that require collaborative action. Here, we describe these challenges - equity in access to kidney failure care, avoiding futile dialysis, reducing dialysis costs, shared decision-making in kidney failure care, living donor risk evaluation and decision-making, priority setting in kidney disease prevention and care, the ethical implications of genetic kidney diseases, responsible advocacy for kidney health and management of conflicts of interest - with the aim of highlighting the need for ethical analysis of specific issues, as well as for the development of tools and training to support clinicians who treat patients with kidney disease in practising ethically and contributing to ethical policy-making.
Assuntos
Nefrologia/ética , Conflito de Interesses , Controle de Custos/ética , Tomada de Decisão Compartilhada , Prioridades em Saúde/ética , Acessibilidade aos Serviços de Saúde/ética , Disparidades em Assistência à Saúde/ética , Humanos , Nefropatias/genética , Transplante de Rim/ética , Futilidade Médica/ética , Tráfico de Órgãos/ética , Defesa do Paciente/ética , Diálise Renal/economia , Diálise Renal/ética , Insuficiência Renal/terapia , Obtenção de Tecidos e Órgãos/éticaRESUMO
The COVID-19 pandemic has raised a host of ethical challenges, but key among these has been the possibility that health care systems might need to ration scarce critical care resources. Rationing policies for pandemics differ by institution, health system, and applicable law. Most seem to agree that a patient's ability to benefit from treatment and to survive are first-order considerations. However, there is debate about what clinical measures should be used to make that determination and about other factors that might be ethically appropriate to consider. In this paper, we discuss resource allocation and several related ethical challenges to the healthcare system and society, including how to define benefit, how to handle informed consent, the special needs of pediatric patients, how to engage communities in these difficult decisions, and how to mitigate concerns of discrimination and the effects of structural inequities.
Assuntos
Comitês Consultivos , Betacoronavirus , Infecções por Coronavirus/epidemiologia , Alocação de Recursos para a Atenção à Saúde/ética , Pneumonia Viral/epidemiologia , Bioética , COVID-19 , Infecções por Coronavirus/prevenção & controle , Humanos , Pandemias/ética , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , SARS-CoV-2 , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: The coronavirus disease 2019 pandemic has or threatens to overwhelm health care systems. Many institutions are developing ventilator triage policies. OBJECTIVE: To characterize the development of ventilator triage policies and compare policy content. DESIGN: Survey and mixed-methods content analysis. SETTING: North American hospitals associated with members of the Association of Bioethics Program Directors. PARTICIPANTS: Program directors. MEASUREMENTS: Characteristics of institutions and policies, including triage criteria and triage committee membership. RESULTS: Sixty-seven program directors responded (response rate, 91.8%); 36 (53.7%) hospitals did not yet have a policy, and 7 (10.4%) hospitals' policies could not be shared. The 29 institutions providing policies were relatively evenly distributed among the 4 U.S. geographic regions (range, 5 to 9 policies per region). Among the 26 unique policies analyzed, 3 (11.3%) were produced by state health departments. The most frequently cited triage criteria were benefit (25 policies [96.2%]), need (14 [53.8%]), age (13 [50.0%]), conservation of resources (10 [38.5%]), and lottery (9 [34.6%]). Twenty-one (80.8%) policies use scoring systems, and 20 of these (95.2%) use a version of the Sequential Organ Failure Assessment score. Among the policies that specify the triage team's composition (23 [88.5%]), all require or recommend a physician member, 20 (87.0%) a nurse, 16 (69.6%) an ethicist, 8 (34.8%) a chaplain, and 8 (34.8%) a respiratory therapist. Thirteen (50.0% of all policies) require or recommend that those making triage decisions not be involved in direct patient care, but only 2 (7.7%) require that their decisions be blinded to ethically irrelevant considerations. LIMITATION: The results may not be generalizable to institutions without academic bioethics programs. CONCLUSION: Over one half of respondents did not have ventilator triage policies. Policies have substantial heterogeneity, and many omit guidance on fair implementation. PRIMARY FUNDING SOURCE: None.
Assuntos
Infecções por Coronavirus/terapia , Pneumonia Viral/terapia , Respiração Artificial/ética , Respiração Artificial/normas , Triagem/ética , Triagem/normas , Betacoronavirus , Bioética , COVID-19 , Política de Saúde , Hospitais , Humanos , Pandemias , SARS-CoV-2 , Inquéritos e Questionários , Estados Unidos , Ventiladores Mecânicos/provisão & distribuiçãoRESUMO
The availability of curative, direct-acting antiviral drugs against hepatitis C virus (HCV) sparks an ethical call for HCV eradication and provides essential tools to spearhead the effort. Challenges include increasing awareness of the chronic hepatitis C epidemic, garnering sufficient public, private, and governmental financial will to invest in the necessary resources, developing pangenotypic drug regimens for global application, and mitigating ethical concerns. To achieve these goals, stakeholders including clinicians, public health professionals, legislators, advocates, and industry can employ a variety of strategies such as increasing HCV screening, implementing treatment as prevention, and improving linkage to care, as well as developing innovative pricing and payment solutions, stimulating innovation through local drug development in high-prevalence regions, continuing vaccine development, and creating efficiencies in the marketing and distribution of educational materials and drug treatments.
Assuntos
Antivirais/farmacologia , Erradicação de Doenças , Hepacivirus/efeitos dos fármacos , Hepatite C/prevenção & controle , Animais , Hepacivirus/fisiologia , Hepatite C/tratamento farmacológico , Hepatite C/virologia , HumanosAssuntos
Medicina Aeroespacial/ética , Astronautas/ética , Pacientes Desistentes do Tratamento , Direitos do Paciente/ética , Seleção de Pacientes/ética , Poder Psicológico , Sujeitos da Pesquisa , Relações Pesquisador-Sujeito/ética , Ensaios Clínicos como Assunto/ética , Confidencialidade , Conflito de Interesses , Contratos , Ética em Pesquisa , Humanos , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Experimentação Humana não Terapêutica/ética , Pesquisadores/ética , Estados Unidos , United States National Aeronautics and Space AdministrationRESUMO
Detection of deception and confirmation of truth telling with conventional polygraphy raised a host of technical and ethical issues. Recently, newer methods of recording electromagnetic signals from the brain show promise in permitting the detection of deception or truth telling. Some are even being promoted as more accurate than conventional polygraphy. While the new technologies raise issues of personal privacy, acceptable forensic application, and other social issues, the focus of this paper is the technical limitations of the developing technology. Those limitations include the measurement validity of the new technologies, which remains largely unknown. Another set of questions pertains to the psychological paradigms used to model or constrain the target behavior. Finally, there is little standardization in the field, and the vulnerability of the techniques to countermeasures is unknown. Premature application of these technologies outside of research settings should be resisted, and the social conversation about the appropriate parameters of its civil, forensic, and security use should begin.
Assuntos
Biotecnologia , Confidencialidade , Detecção de Mentiras , Neurociências , Variações Dependentes do Observador , Privacidade , Biotecnologia/ética , Biotecnologia/instrumentação , Biotecnologia/métodos , Biotecnologia/tendências , Encéfalo/fisiologia , Coerção , Fatores de Confusão Epidemiológicos , Campos Eletromagnéticos , Liberdade , Humanos , Imageamento por Ressonância Magnética/ética , Neurociências/ética , Neurociências/instrumentação , Neurociências/métodos , Neurociências/tendências , Personalidade , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Projetos de Pesquisa , Sensibilidade e Especificidade , Estados UnidosRESUMO
Major advances in the testing of oral fluid (e.g., saliva) may lead to the diagnosis and treatment of previously undiagnosed conditions and may enable dentists to manage oral disease more effectively. Such use of another body fluid, blood, is already well established. Blood is a complex tissue that has been extensively researched and is now used for a wide variety of diagnostic tests. It is also regarded as a form of property with ethical and legal dimensions. If saliva is to fulfill a similar role, it should perhaps be granted those same protections. This paper advances the concept that saliva should be considered a form of property, possibly within personal biological materials law. The emerging potential for the development of marketable products from oral fluids raises the issue of protecting the research participant's ethical and legal rights. In particular, violation of privacy and genetic discrimination may arise from the testing of salivary DNA. Respect for autonomy requires that the clinician inform a patient or research participant about his or her rights to property and privacy as these may pertain to oral fluid.